Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
DCTH:NASDAQ
Delcath Systems Inc
$10.64
-4.92%
(-0.55) 1D
$10.48
-1.50% (-0.16)
After hours
Closed: Apr 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DCTH...
Open
$11.20
High
$11.20
Low
$10.58
Mkt. cap
366.60M
Avg. vol.
314.26K
Volume
1.00
P/E ratio
157.30
52-wk high
$18.23
52-wk low
$8.12
EPS
$0.07
Beta
0.44
Shares outstanding
34.46M
No. of employees
156
News stories
From sources across the web
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees156
Founded1988
HeadquartersQueensbury, New York, United States
SectorMedical device
Websitedelcath.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
19.78M
24.16M
20.56M
20.73M
Cost of goods sold
2.84M
3.32M
2.62M
3.01M
Cost of revenue
2.84M
3.32M
2.62M
3.01M
Research and development expenses
5.01M
6.88M
7.99M
9.37M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.29M
11.37M
10.34M
10.53M
Operating expense
16.30M
18.25M
18.33M
19.90M
Total operating expenses
19.14M
21.57M
20.95M
22.91M
Operating income
642.00K
2.59M
-388.00K
-2.18M
Other non operating income
4.00K
-34.00K
-33.00K
-7.00K
EBT including unusual items
1.26M
3.20M
375.00K
-1.33M
EBT excluding unusual items
1.26M
3.20M
375.00K
-1.33M
Income tax expense
195.00K
508.00K
-455.00K
562.00K
Effective tax rate
15.43%
15.85%
-121.33%
-42.13%
Other operating expenses
-
-
-
-
Net income
1.07M
2.70M
830.00K
-1.90M
Net profit margin
5.40%
11.16%
4.04%
-9.15%
Earnings per share
0.03
0.07
0.02
-0.05
Interest and investment income
618.00K
649.00K
796.00K
857.00K
Interest expense
-
-
-
-
Net interest expenses
618.00K
649.00K
796.00K
857.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
685.00K
2.64M
-324.00K
-2.10M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer